期刊文献+

基于多成分含量测定及色谱指纹图谱技术提升白术药材质量标准 预览

Improving Quality Standard of Atractylodis Macrocephalae Rhizoma by Using Multi-component Content Determination and Chromatographic Fingerprint Technology
在线阅读 下载PDF
收藏 分享 导出
摘要 目的:本文拟建立白术药材的含量测定和液相色谱指纹图谱评价方法,提出其主要活性成分白术内酯I-Ⅲ的含量限度以及白术药材特征色谱峰,为白术药材质量标准的提升和完善提供参考。方法:系统地收集7个省市共38批白术药材,采用HPLC-DAD方法建立指纹图谱,并测定白术内酯Ⅰ、Ⅱ、Ⅲ的含量,结合相似度、系统聚类以及主成分分析法进行综合性分析。结果:38份白术药材样品中白术内酯Ⅰ、Ⅱ、Ⅲ的含量分别为(0.101±0.044)%、(0.028±0.021)%和(0.041±0.045)%;指纹图谱中有21个共有峰,并选定其中10个较为明显的色谱峰作为白术药材的特征峰;综合分析显示,产地是影响白术药材内在质量差异的重要因素。结论:不同来源白术药材内在质量差异较大,所建立的含量测定方法和指纹图谱技术能够较准确反映药材质量,且两者结果较为一致,考虑到不同来源样品含量差异大,根据稳定性较高的道地产区浙江产白术的含量测定结果,建议白术内酯Ⅰ、Ⅱ、Ⅲ的最低含量限度分别为0.082%、0.014%和0.013%,可为2020版《中华人民共和国药典》关于白术药材质量标准的修订提供参考。 Objective:This study is aimed to establish an evaluation method of Atractylodis Macrocephalae Rhizoma by the content determination and chemical chromatographic fingerprint,and propose the content limitations of the active ingredients,atractylenolide Ⅰ-Ⅲ,as well as the characteristic fingerprint of Atractylodis Macrocephalae Rhizoma. Methods:38 batches of samples were collected from 7 provinces in the main producing areas.An HPLC-DAD method was used to establish fingerprints,as well as to determine the content of atractylenolides Ⅰ,Ⅱ and Ⅲ.Similarity analysis,systematic clustering,and principal component analysis were then conducted for comprehensive analysis. Result:The contents of atractylenolides Ⅰ,Ⅱ and Ⅲ in 38 samples were (0.101±0.044 )%,(0.028±0.021 )% and (0.041±0.045 )%,respectively;there were 21common peaks in the fingerprint profiling,and 10 of them were selected as the characteristic peaks of Atractylodis Macrocephalae Rhizoma.The comprehensive analysis showed that the origin was an important factor of the intrinsic quality of Atractylodis Macrocephalae Rhizoma. Conclusion:The intrinsic quality of Atractylodis Macrocephalae Rhizoma differs greatly among different origins.The established content determination method and fingerprinting technique can reflect the quality of Atractylodis Macrocephalae Rhizoma accurately.While samples of Zhejiang province are with higher stability,it is suggested that the minimum limits of atractylenolides Ⅰ,Ⅱ and Ⅲ are 0.082%,0.014% and 0.013%,respectively.Our results can provide a reference for the Chinese Pharmacopoeia (2020 version )on the quality standards of Atractylodis Macrocephalae Rhizoma.
作者 刘青 申洁 肖苏萍 郭凯 何春年 王继永 LIU Qing;SHEN Jie;XIAO Su-ping;GUO Kai;HE Chun-nian;WANG Ji-yong(Institute of Medicinal Plant Development,Chinese Academy of Medical Sciences,Peking Union Medical College,Beijing 100193,China;Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine,Ministry of Education,Beijing 100193,China;China National Traditional Chinese Medicine,Beijing 100195,China)
出处 《中国现代中药》 CAS 2019年第8期1062-1067,共6页 Modern Chinese Medicine
基金 国家中药标准化项目(ZYBZH-C-GD-08).
关键词 白术药材 含量测定 指纹图谱 含量限度 Atractylodis Macrocephalae Rhizoma content determination fingerprint content limitation
作者简介 通信作者:何春年,研究员,研究方向:药用植物亲缘学研究与中药质量评价,Tel:(010)57833165,E-mail:cnhe@implad.ac.cn;通信作者:王继永,研究员,研究方向:中药资源研究与产业化,Tel:(010)89259576,E-mail:wangjiyong75@163.com.
  • 相关文献

参考文献6

二级参考文献52

共引文献58

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈